0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Pegaspargase is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2016-01-14
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No